Medicus Pharma Ltd.
corporate_fare Company Profile
Medicus Pharma Ltd. (NASDAQ:MDCX) is a publicly traded company in the Life Sciences sector. Wiseek has independently scored 36 items for MDCX at importance 7 or higher on its 1–10 market-impact scale. Its most recent item scored 7 or higher is dated 2026-10-23, rated 8/10. Across its 20 most recent items scored 7 or higher, the top rating is 9/10, with 15 rated 8 or above. Recent SEC coverage for MDCX spans 8-K, PRE 14A, 10-Q, 424B3.
Recent high-impact activity:
- Medicus Pharma Regains Nasdaq Bid Price Compliance Days After Delisting Determination
- Medicus Pharma Seeks Blank-Cheque Preferred Shares and Up-to-50:1 Forward Split at Dec 2 Meeting
- Medicus Pharma Moves to Regain Nasdaq Compliance with 50-to-1 Reverse Split
- Medicus Pharma Files Seamless Phase 2b/3 Protocol for Teverelix, Cutting Enrollment to ~600
- Medicus Pharma Pivots SkinJect to Gorlin Syndrome, Drops nBCC Development
Financial Snapshot
Short Interest & Short Volume
1.00 days to coverFINRA reported short interest of 43,628 shares in MDCX as of the October 15, 2026 settlement, a 98.8% decrease from the prior period — about 1.0 days to cover at its recent average daily volume. On October 30, 2026, 43.7% of MDCX volume reported to FINRA trade-reporting facilities was marked short.
Daily short sale volume covers trades reported to FINRA trade-reporting facilities and is not the same as short interest (bi-monthly reported positions). Source: FINRA — FINRA is the owner and source of this short interest and short sale volume data; it may not be redistributed.
Dilution Risk
High riskFiling-implied dilution signals for MDCX, detected from its recent SEC filings · based on capital-structure filings through 2026-10-23.
Highly Dilutive ATM Sales · Going Concern Warning
A filing-implied signal, not a realized share count. How Wiseek tracks dilution →